Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020833 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Alwah R Al-Ghamdi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Chalcones, Chalcone, Receptors, Estrogen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Researchers Supporting Project number (RSP2024R207), King Saud University, Riyadh, Saudi Arabia., King Saud University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
Cancer remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for novel therapeutic agents. This study investigated the synthesis and biological evaluation of O-alkyl (E)-chalcone derivatives (4a–4v) as potential anticancer agents. The compounds were synthesized via aldol condensation of substituted aldehydes and acetophenones, with structures confirmed by IR, NMR, and mass spectrometry. In vitro cytotoxicity assays revealed varying effectiveness, with compounds 4a, 4b, 4q, and 4v exhibiting potent activity against MDA-MB-231 and MCF-7, showing IC50 values between 2.08 and 13.58 µM, besides HCT-116 and HeLa cancer cell lines (IC50 values between 6.59 and 22.64 µM). Notably, compound 4b displayed remarkable selectivity, with an IC50 of 54.59 µM against the non-cancerous WI-38 cell line. Additionally, protein kinase inhibition assays indicated that compounds 4b and 4q effectively inhibited EGFR and VEGFR-2, with 4b outperforming the standard inhibitor erlotinib. Molecular docking studies of compound 4q showed strong binding affinities in the ATP-binding pockets of EGFR, HER2, VEGFR2, and CDK2. In silico analyses further highlighted the favorable pharmacokinetic properties of compound 4q, underscoring its potential as a selective tyrosine kinase inhibitor. These findings suggest the therapeutic promise of O-alkyl (E)-chalcone derivatives in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
ORCID-Profile: Alwah R Al-Ghamdi, Reem I Al-Wabli, Maha S Al-Mutairi, A F M Motiur Rahman
Förderung
- Researchers Supporting Project number (RSP2024R207), King Saud University, Riyadh, Saudi Arabia.
- King Saud University, Riyadh, Saudi Arabia
Zitieren
APA
Al-Ghamdi, A. R., Ahmed, W. U., Al-Wabli, R. I., Al-Mutairi, M. S., & Rahman, A. F. M. M. (2025). Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020833
Vancouver
Al-Ghamdi AR, Ahmed WU, Al-Wabli RI, Al-Mutairi MS, Rahman AFMM. Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020833
BibTeX
@article{AlGhamdi2025,
author = {Al-Ghamdi, Alwah R and Ahmed, Wahid U and Al-Wabli, Reem I and Al-Mutairi, Maha S and Rahman, A F M Motiur},
title = {Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020833}
}
EUVIMED